innoscripta SE, a German provider of R&D management software, has announced its expansion into the United Kingdom, marking a significant step in its international growth strategy. The company, which recently entered the French market, has established a dedicated UK sales team and secured its first customer in the region, a software firm with annual revenues in the mid-double-digit million euro range.
The UK represents one of Europe’s largest R&D tax incentive markets, with annual reliefs of approximately EUR 8.7 billion, roughly 0.3% of GDP—about seven times larger than Germany. This market size, coupled with increasingly stringent documentation requirements from HM Revenue & Customs (HMRC), presents a compelling opportunity for innoscripta’s SaaS platform, Clusterix.
Clusterix is designed to help companies systematically capture R&D projects, working hours, and eligible costs while creating a comprehensive, audit-ready documentation trail. The platform has been fully adapted to UK regulatory requirements, addressing the tightened compliance standards that HMRC has imposed in recent years. This capability is particularly valuable as businesses face greater scrutiny over their R&D tax relief claims.
“The UK is a key market for us, given its substantial R&D tax incentive framework and the growing need for digital solutions to manage compliance,” said a spokesperson for innoscripta. The company has already advanced negotiations with several additional potential customers and plans to significantly expand its UK sales organization and customer base by the end of the year.
The expansion follows innoscripta’s successful market entry into France, as announced in a news release dated 15 April 2026. With the UK now added to its portfolio, innoscripta is positioning itself as a key player in Europe’s R&D tax relief ecosystem, helping companies navigate complex regulatory landscapes while maximizing their innovation incentives.
For businesses operating in the UK, the adoption of platforms like Clusterix could become increasingly important as HMRC continues to tighten its oversight. The software not only streamlines the claims process but also provides a robust defense in the event of an audit, a critical consideration for companies seeking to leverage R&D tax reliefs effectively.
innoscripta SE, listed under ISIN DE000A40QVM8, offers Clusterix as a scalable platform for the structured organization and management of research and development activities. The company’s expansion into the UK underscores its commitment to becoming a leading provider of R&D management solutions across Europe.
